78 F
New York
Saturday, July 2, 2022

Glaukos Corporation [NYSE: GKOS] Inks Agreement with Santen Pharmaceutical

Must read

Glaukos Corporation [NYSE: GKOS] declared that it has signed a development and commercialization license agreement with Santen Pharmaceutical Co., Ltd. (Santen) for the PRESERFLO MicroShunt. This new agreement is the substitute for earlier partnership and distribution agreements between the two parties.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

As per the agreement, Glaukos receive special commercialization rights for the MicroShunt in New Zealand, Canada, Brazil, Mexico, the US, and Australia the rest of Latin America. Furthermore, this new agreement also provides GKOS full control over all development activities for the MicroShunt in these same areas. It involves overall clinical development and regulatory affairs activities in the US after a transition period.

Additionally, Santen also lodged a premarket approval (PMA) application to the U.S. FDA in June 2020, and negotiations with the FDA are underway. Santen will continue to produce and supply the MicroShunt for the Glaukos areas and lead development and marketing activities somewhere else. The firm has not yet revealed the financial terms of the agreement.

The PRESERFLO MicroShunt is an ab-externo, a drainage system. It assists in the drain of eye fluid. It also lessens IOP in sufferers with primary open-angle glaucoma whose IOP is not controlled when using maximum tolerated glaucoma medications or where glaucoma progression warrants surgery. To reduce glaucoma and vision loss only thing which works is to reduce IOP.

More articles

Latest article

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam